EMA committee backs Zealand Pharma’s Zeydovio for short bowel syndrome

The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on 18 September for Zeydovio, Zealand Pharma's treatment for short bowel syndrome. Reuters first carried the committee result. A positive CHMP opinion is not a licence. It is the scientific recommendation that the European Commission normally turns into a marketing authorisation in about 60 days. If the Commission follows the committee, Zeydovio becomes available across the EU, with national pricing fights still to come.

Short bowel syndrome appears after large parts of the small intestine are removed or fail. Patients cannot absorb enough fluid and nutrients. Many live on parenteral nutrition, an intravenous feed that ties them to pumps, line infections and hospital time. A drug that cuts the days on the drip is measured in fewer night feeds and fewer catheter crises, not in abstract quality scores.

Why a mid-size Danish firm is in this file

Zealand Pharma, listed in Copenhagen, has spent years on peptide drugs for metabolic and rare gastrointestinal disease. Short bowel is a small market with a high cost per patient. That mix draws specialists and scares mass-market companies. A CHMP yes is the event that lets Zealand talk to payers with a label in hand rather than a trial slide.

The committee's job is to decide whether the benefit-risk balance holds for the claimed indication. It does not set a price. Germany, France and Italy will each run their own reimbursement clocks. Orphan-style products in this corner of gastroenterology often launch first in a handful of reference centres, then widen if hospitals can see a drop in parenteral-nutrition spend.

Investors will treat Friday as a binary win. Clinicians will wait for the exact wording of the indication, the dose, and the monitoring requirements. Those details sit in the CHMP assessment report that follows the opinion. Until that document is public, claims about how many days off intravenous nutrition a typical patient might gain should stay inside the trial numbers Zealand has already released in earlier scientific meetings.

What comes next

The Commission decision is the next official act. Parallel advice in Britain, if Zealand files there, is a separate dossier. US regulators have their own clock. For European patients the useful date is not 18 September. It is the day a hospital pharmacy can order the pack and a specialist can write the first prescription under a reimbursed code.

Rare-disease files move slowly after a committee smile. Manufacturing, risk-management plans and registry follow-up all have to be in place. Zeydovio now has the scientific green light that those steps require. The patients who have been counting nights on a pump will count weeks until the Commission text is signed.